Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) shot up 6.7% during trading on Monday . The stock traded as high as $11.29 and last traded at $11.10. 12,653 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 75,727 shares. The stock had previously closed at $10.40.
Gyre Therapeutics Stock Up 4.1 %
The firm’s 50 day moving average is $12.17 and its 200 day moving average is $14.53.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million during the quarter. As a group, analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.
Insider Activity at Gyre Therapeutics
Institutional Trading of Gyre Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new stake in Gyre Therapeutics in the second quarter valued at $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $166,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $218,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $220,000. Institutional investors own 23.99% of the company’s stock.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- How to Invest in Silver: A Beginner’s Guide
- What is the Shanghai Stock Exchange Composite Index?
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Dividend Capture Strategy: What You Need to Know
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.